Institutional Investor Files Intent to Sell $123K in Shares Amid Ongoing Exit
HOWL is trading near its 52-week low of $0.493 (0.4% above the low).
Summary
UBS Oncology Impact Fund, L.P., an institutional shareholder, filed a Form 144 indicating intent to sell approximately $123,768 worth of common stock, continuing a pattern of institutional distribution.
Key Events · Ownership and Investor Activity · HOWL
-
Intent to Sell Shares
UBS Oncology Impact Fund, L.P. filed a Form 144 to sell 240,280 shares of common stock, valued at approximately $123,768.
-
Continuation of Institutional Exit
This filing follows a series of recent Form 144s and Schedule 13D/A filings by institutional investors, including MPM BioVentures and RA Capital, indicating ongoing significant sales totaling over $800,000 in the past month.
-
Distressed Company Context
The company previously disclosed substantial doubt about its ability to continue as a going concern and is exploring strategic alternatives, making continued institutional selling particularly notable.
-
Trading Near 52-Week Lows
The proposed sale occurs while the stock is trading near its 52-week low, reinforcing the negative sentiment from institutional exits.
Analysis · HOWL · Life Sciences
This Form 144 from UBS Oncology Impact Fund, L.P. signals a continuation of institutional investors reducing their exposure to Werewolf Therapeutics. While the individual transaction value of $123,768 is modest, it adds to a pattern of significant sales by major institutional holders, including MPM BioVentures and RA Capital, totaling over $800,000 in the past month. This ongoing distribution is particularly concerning given the company's recent disclosure of substantial doubt about its ability to continue as a going concern and its exploration of strategic alternatives. The fact that these sales are occurring while the stock trades near its 52-week low suggests a lack of confidence from these large shareholders.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $0.49 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.